Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tucidinostat + azacitidine + cyclophosphamide + epirubicin + vindesine + prednisone
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
Tucidinostat + azacitidine + cyclophosphamide + epirubicin + vindesine + prednisone (also referred to as AC-CHOP in clinical trial contexts) is an experimental combination regimen being evaluated for the first-line treatment of peripheral T-cell lymphoma (PTCL). The regimen combines two epigenetic modulators—tucidinostat (a subtype-selective HDAC inhibitor targeting HDAC1, 2, 3, and 10) and azacitidine (a DNA methyltransferase inhibitor)—with a modified CHOP chemotherapy backbone. This approach is based on the premise that epigenetic priming with HDAC inhibitors and hypomethylating agents can sensitize T-cell lymphoma cells to conventional cytotoxic chemotherapy. Peking Union Medical College Hospital is the lead sponsor for a Phase III trial investigating this combination's efficacy and safety compared to standard CHOP in untreated patients.
- Other names
- tucidinostat + azacitidine + CHOPchidamide + azacitidine + CHOPHBI-8000 + azacitidine + CHOP
02
Targets
DNADNMT1 (DNA (cytosine-5)-methyltransferase 1)GR (Glucocorticoid receptor)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on tucidinostat + azacitidine + cyclophosphamide + epirubicin + vindesine + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tucidinostat + azacitidine + cyclophosphamide + epirubicin + vindesine + prednisone.